# XBiotech Inc.: overview XBIT · Nasdaq · CIK 1626878 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/xbit.md) · [Financials](/companies/xbit/financials.md) · [Filings](/companies/xbit/filings.md) · [Insiders](/companies/xbit/insiders.md) Latest reported revenue: [$0](/filings/0001171843-24-001382.md) for Q4 FY2023, three months to 2023-12-31, from the 10-K filed Mar 15, 2024 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001171843-24-001382). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(6.2) d](/filings/0001171843-25-007233.md) | [(6.6) d](/filings/0001171843-26-001561.md) | [(6.8)](/filings/0001171843-26-003419.md) | [(6.0) d](/filings/0001171843-26-005492.md) | [(4.4) d](/filings/0001171843-25-007233.md) | [(23.0) d](/filings/0001171843-26-001561.md) | [(9.0)](/filings/0001171843-26-003419.md) | [(4.5) d](/filings/0001171843-26-005492.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [18.4](/filings/0001171843-23-001705.md) | [4.0](/filings/0001171843-24-001382.md) | [0.0](/filings/0001171843-24-001382.md) | not reported | not reported | | Gross margin | % | [68.4%](/filings/0001171843-23-001705.md) | [83.8%](/filings/0001171843-24-001382.md) | not reported | not reported | not reported | | Operating margin | % | [(136.4%)](/filings/0001171843-23-001705.md) | [(860.1%)](/filings/0001171843-24-001382.md) | not reported | not reported | not reported | | Net margin | % | [(94.7%)](/filings/0001171843-23-001705.md) | [(820.4%)](/filings/0001171843-24-001382.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.58)](/filings/0001171843-23-001705.md) | [(1.08)](/filings/0001171843-24-001382.md) | [(0.81)](/filings/0001171843-25-001527.md) | [(1.26)](/filings/0001171843-26-001561.md) | [(1.49)](/filings/0001171843-26-001561.md) | | Free cash flow | $m | [65.9](/filings/0001171843-23-001705.md) | [(15.4)](/filings/0001171843-24-001382.md) | [(19.1)](/filings/0001171843-25-001527.md) | [(32.3)](/filings/0001171843-26-001561.md) | [(40.2)](/filings/0001171843-26-001561.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xbit/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $738.6k | 321,146 | | Added +28,042 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $492.8k | 214,116 | | Reduced −16,904 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $460.4k | 200,182 | | Reduced −789 | | [RBF Capital, LLC](/funds/1134621.md) | 2026-06-30 | $456.6k | 198,501 | | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $340.1k | 147,880 | | Reduced −17,674 | | [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $226.4k | 98,447 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $212.4k | 92,365 | | Added +789 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $182.5k | 79,330 | | Reduced −26,210 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $171.8k | 74,700 | Call | New +74,700 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $167.9k | 73,006 | | Unchanged | ## Recent filings [All 403 filings](/companies/xbit/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-02 | 11:13 ET | [DEF 14A](/filings/0001171843-26-006362.md) | Proxy statement, period 2026-11-24 | 0001171843-26-006362 | | 2026-08-13 | 11:26 ET | [10-Q](/filings/0001171843-26-005492.md) | Quarterly report, period 2026-06-30 | 0001171843-26-005492 | | 2026-05-14 | 14:43 ET | [10-Q](/filings/0001171843-26-003419.md) | Quarterly report, period 2026-03-31 | 0001171843-26-003419 | | 2026-04-29 | 13:02 ET | [10-K/A](/filings/0001171843-26-002814.md) | Annual report, amended, period 2025-12-31 | 0001171843-26-002814 | | 2026-03-13 | 14:33 ET | [10-K](/filings/0001171843-26-001561.md) | Annual report, period 2025-12-31 | 0001171843-26-001561 | | 2025-12-09 | 09:00 ET | [8-K](/filings/0001171843-25-007836.md) | 5.02 Departure or appointment of officers or directors | 0001171843-25-007836 | | 2025-11-12 | 11:45 ET | [10-Q](/filings/0001171843-25-007233.md) | Quarterly report, period 2025-09-30 | 0001171843-25-007233 | | 2025-10-15 | 12:54 ET | [8-K/A](/filings/0001171843-25-006441.md) | 5.02 Departure or appointment of officers or directors | 0001171843-25-006441 | | 2025-10-03 | 11:15 ET | [8-K](/filings/0001171843-25-006266.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001171843-25-006266 | | 2025-09-02 | 13:10 ET | [8-K](/filings/0001171843-25-005673.md) | 5.07 Shareholder vote results | 0001171843-25-005673 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001171843-26-001561.md), filed Mar 13, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1626878 - Tickers: XBIT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A1 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 09:40 ET. No prices; not investment advice.